Materialise is exiting the parts of additive manufacturing that never earned their keep and concentrating the franchise on personalized medical work. The second-quarter print is the first clean look at that sharper company. Medical devices and services carried the growth. Aerospace series manufacturing returned after a long prototyping slump. Management raised full-year adjusted operating profit even while holding revenue guidance unchanged. The equity debate is whether that profit lift is a durable mix shift or a quarter that borrowed from cost cuts and an easier currency compare.
Medical now supplies more than half of group sales. Segment revenue rose 12 percent, and device and service work grew 19 percent even as medical software slipped. Manufacturing grew because aerospace sales jumped 40 percent, yet the shop is still just shy of break-even. Software contracted again as industrial buyers stretched cycles and academic labs in the United States lost grant funding. Profitability outran the top line because operating costs were held and two non-core lines were pushed out the door.
Adjusted operating profit rose faster than sales, and first-half free cash flow covered a running buyback without denting a net-cash balance near $85 million. Full-year sales guidance stays in a band around $320 million even after the RapidFit and Eyewear exits. The raised profit range now sits near $15 million at the midpoint. The next several prints decide whether medical devices keep compounding at a low-double-digit clip and whether manufacturing can stay above water once the aerospace bounce is no longer new.